WebInitial investigations revealed that EGFR-mutated NSCLC has lower PD-L1 expression and a low tumor mutational burden, thus leading to weak immunogenicity. Moreover, the use of … WebGefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, …
EGFR blockade activates interferon Nature Cancer
WebDysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to … WebMar 12, 2024 · Immune checkpoint inhibitors (ICIs) have recently been highlighted for their functions in blocking the effect of inhibitory immune molecules on T cells and thus reducing immune tolerance to cancers; these ICIs have been widely analyzed by … cory cielinski texas facebook page
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
WebOct 13, 2024 · In vitro experiments suggested that ARID1A-KD activates the EGFR/PI3K/Akt/mTOR pathway and inhibits autophagy, which attenuates the inhibition of Rig-I-like receptor pathway activity and type I interferon production in EGFR … WebOct 24, 2024 · These data suggest that, similar to what we observed for epidermal growth factor receptor (EGFR) blockade, MEK inhibition activates a type I interferon … WebApr 6, 2024 · Inhibiting mutant EGFR triggers type I interferon (IFN)-I upregulation via a RIG-I–TANK-binding kinase 1 (TBK1)–IRF3 pathway. The ubiquitin ligase TRIM32 … breach poe filters